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Abstract
Background: A number of studies indicate a link between cannabis-use and psychosis as well as
more severe psychosis in those with existing psychotic disorders. There is currently insufficient
evidence to decide the optimal way to treat cannabis abuse among patients with psychosis.
Objectives: The major objective for the CapOpus trial is to evaluate the additional effect on
cannabis abuse of a specialized addiction treatment program adding group treatment and
motivational interviewing to treatment as usual.
Design:  The trial is designed as a randomized, parallel-group, observer-blinded clinical trial.
Patients are primarily recruited through early-psychosis detection teams, community mental health
centers, and assertive community treatment teams. Patients are randomized to one of two
treatment arms, both lasting six months: 1) specialized addiction treatment plus treatment as usual
or 2) treatment as usual. The specialized addiction treatment is manualized and consists of both
individual and group-based motivational interviewing and cognitive behavioral therapy, and
incorporates both the family and the case manager of the patient.
The primary outcome measure will be changes in amount of cannabis consumption over time.
Other outcome measures will be psychosis symptoms, cognitive functioning, quality of life, social
functioning, and cost-benefit analyses.
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Background
A recent meta-analysis of eleven longitudinal studies con-
cluded that cannabis use is associated with increased risk
of lasting psychotic conditions later in life [1]. Assuming
causality, as much as 800 annual cases of schizophrenia
are preventable in the UK if exposure to cannabis was
eliminated [2]. Several studies have shown that use of can-
nabis increases the risk of developing schizophrenia-like
symptoms, especially in young men disposed to develop-
ing psychosis [3-10]. Furthermore, use of cannabis among
patients with psychosis can maintain and worsen the psy-
chotic symptoms [11-15], and comorbid schizophrenia
and substance abuse is associated with lack of compliance
to treatment and with more rehospitalizations [15-20].
This indicates both that effective interventions to limit
cannabis use in persons with psychosis are needed, and
that getting patients to follow such interventions may be
difficult.
A randomized trial showed that the combination of cog-
nitive behavioral therapy, motivational interviewing [see
[21]], and family involvement had a significant positive
effect on level of functioning, psychotic symptoms, and
duration of periods of cannabis-abstinence, compared
with regular treatment [22]. This finding has been sup-
ported by two reviews, concluding that positive evidence
exists for integrated treatment with motivational inter-
views, cognitive behavioral therapy (individual or group-
based), and a harm-reduction approach [23,24]. Group-
based treatments are arguably less expensive, and in a lit-
erature review, Weiss et al. concluded that specialized
group therapy could reinforce the effect of an existing
treatment [25]. However, there is currently insufficient
evidence to show that group-based interventions for can-
nabis use are superior to individual treatment [26,27].
Similarly, authors of a recent Cochrane review concluded
that insufficient evidence exists to show that any psycho-
social treatment method for comorbid schizophrenia and
substance abuse is superior to others [28].
Objectives of the CapOpus trial
We plan to undertake a trial in which combined group-
based and individual treatment, incorporating motiva-
tional interviewing, psycho-education, cognitive behavio-
ral therapy, and social skills training in addition to
treatment as usual, is compared with treatment as usual.
The primary outcome will be change in number of days
abstinent from cannabis within the preceding 30-day
period as measured with the Time-Line Follow Back
(TLFB) instrument [29,30].
Methods
The trial is designed as a two-armed, parallel-group,
observer-blinded randomized clinical superiority trial
(Figure 1). Patients will receive either specialized CapO-
pus treatment or treatment as usual, as described below.
CapOpus intervention – the experimental intervention
The contents of the CapOpus intervention are briefly
schematized in figure 2. An important part of the CapO-
pus treatment is to help the patient understand the mech-
anisms that complicate cessation of cannabis use. The
overall target is harm reduction, i.e. that harm from can-
nabis consumption is thought to be alleviated even if con-
sumption is not terminated, only reduced. This is a
method that has proved effective in several studies
[23,24]. The CapOpus intervention consists of one month
of individual treatment, followed by a three-month group
treatment in combination with individual treatment, and
followed by two months of individual treatment. The con-
tents of each of these three stages will be described in
detail below.
Upon inclusion, the patient's case manager at the referring
institution will be offered education and supervision by
one of the addiction consultants employed in the CapO-
pus trial.
During the first month, one of the addiction consultants
will be in contact with each patient once or twice a week.
A meeting will be held with the patient's family, and there
will be contact with the case manager every two weeks.
During the three months of group intervention, one of the
addiction consultants will have weekly individual con-
tacts with the patient and two meetings with the family. In
addition, the patient will follow a weekly group interven-
tion and have consultative contacts with the case manager
every two weeks. During the two months following the
group intervention, the addiction consultants will be in
weekly contact with the patient and the family will be
invited to a meeting. The addiction consultants will con-
tact the patient's case manager every three weeks.
For the purpose of enhancing alliance and motivation, the
treatment will start with motivational interviewing with
the patient being aided in analyzing advantages and draw-
backs of continued use of cannabis [21,31]. There is good
evidence for the efficacy of motivational interviews in
short-term treatment [32,33]. The patient will formulate
individual goals for the treatment and be offered the
group intervention. The groups will consist of six to eight
patients, with the addiction consultants as trainers. Each
group will run for three months with weekly sessions last-
ing 1 1/2 hour. The intervention methods will gradually
shift from motivational interviewing to cognitive behav-
ioral therapy as the patients become more motivated to
change their cannabis use. There will be emphasis on ana-
lyzing advantages and disadvantages of continued use,
instructions in coping skills in relation to craving and sit-Trials 2008, 9:42 http://www.trialsjournal.com/content/9/1/42
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uations that usually trigger cannabis use, and in develop-
ing personal strategies for avoiding or handling these
situations.
The group intervention will be followed by two months
during which weekly meetings with the patient continue.
The addiction consultants offer consultative assistance to
the patient's case manager, as well as meeting the patient's
family. The purpose is to mediate methods of the inter-
vention to the network surrounding the patient in order to
prolong beneficial effects.
To increase adherence to treatment, positive reinforce-
ment will be applied through contingency management
in the form of complimentary food and social experi-
ences, which may enhance outcomes of cognitive behav-
ioral therapy or motivational enhancement [34].
Contingency management in the CapOpus trial will have
no connection to whether or not the use of cannabis is
decreased.
The experimental CapOpus intervention is offered in
addition to treatment as usual. The interventions offered
to the patients will be registered so that it will be possible
to estimate if the two intervention groups receive different
forms of treatment as usual.
Control treatment – treatment as usual
The control treatment consists of receiving the treatment
that would have been available without participation in
the trial, i.e. treatment as usual. The patient's case man-
ager will carry out the control treatment. In essence, treat-
ment as usual for cannabis abuse is part of the existing,
manualized psychosocial and/or pharmaceutical treat-
Flowchart of the CapOpus trial Figure 1
Flowchart of the CapOpus trial. See text for further information.Trials 2008, 9:42 http://www.trialsjournal.com/content/9/1/42
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ment for psychotic illness; however, no explicit manual
exists on ways in which cannabis abuse should be
approached. Treatment as usual is thus not expected to be
uniform. In particular, frequency of contacts may vary
between case managers, and this will be registered and
analyzed. However, the heterogeneous nature of the con-
trol treatment accurately reflects the current situation in
Denmark, and we therefore consider this to be the appro-
priate treatment for analytical control.
Treatment as usual is carried out in one of three estab-
lished facilities; the OPUS teams for early detection and
treatment of young people with psychosis [35], the com-
munity mental health centers (CMHC) [36], and the
assertive community treatment (ACT) teams [37]. The
effect of treatment as usual on cannabis abuse in Denmark
is unknown, but a randomized trial comparing OPUS
treatment with other treatment (primarily CMHC) inves-
tigated prevalence of any comorbid diagnosis of harm or
dependence syndrome at baseline and at one and two
years follow-up. At baseline, 27% in both treatment arms
had such a comorbidity, which decreased to 16 – 17% for
OPUS patients and 21 – 22% for other patients [38].
Recruitment and criteria for inclusion and exclusion
Physicians and therapists in the Danish municipalities of
Copenhagen and Frederiksberg (henceforth collectively
referred to as Copenhagen) are informed of the CapOpus
trial through meetings and leaflets. In particular, OPUS,
CMHC, and ACT-teams are targeted. Patients referring
themselves and patients referred by general practitioners
will be associated with one of these institutions prior to
inclusion.
Inclusion criteria are presented in Table 1. The diagnostic
criteria are based on the ICD-10 system [39].
The age group is selected both to ensure a relatively
homogenous group of patients, and to reflect the age
group at highest risk of developing schizophrenia [40].
The criterion for residence in the Copenhagen area is an
attempt to maximize adherence to treatment by minimiz-
ing the distance to treatment facilities. If this criterion
Schematic timeline of the CapOpus intervention Figure 2
Schematic timeline of the CapOpus intervention.
Table 1: Criteria for inclusion and exclusion in the CapOpus trial.
Inclusion: Exclusion:
ICD-10 diagnosis F2 (F20–F29): Schizophrenia, schizotypal and delusional disorders ICD-10 diagnosis F10.2: Alcohol dependence syndrome
ICD-10 diagnosis F11.2: Opioid dependence syndrome
ICD-10 diagnosis F12: Mental and behavioral disorders due to use of cannabinoids ICD-10 diagnosis F14.2: Cocaine dependence syndrome
Aged 18–35 years Refusal to give informed consent
Residence in the Copenhagen area
Sufficient Danish-speaking capabilities
Able and willing to give informed consentTrials 2008, 9:42 http://www.trialsjournal.com/content/9/1/42
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leads to insufficient numbers of included patients, expan-
sion of the geographic area of the trial will be considered.
Patients must speak and understand Danish sufficiently to
participate in both treatment and assessment without an
interpreter.
The diagnostic criteria for exclusion are chosen so as to
decrease the risk of treatment effects becoming con-
founded by the presence of other dependence syndromes.
Only dependence syndromes of alcohol, opioids, and
cocaine are cause for exclusion – more sporadic uses of
these substances are not.
Assessments
Patients are subjected to three almost identical assess-
ments. The first assessment occurs at baseline before ran-
domization, because information from the baseline
assessment is used to perform stratified randomization
and to validate inclusion and exclusion criteria. The sec-
ond assessment occurs six months after the baseline
assessment, when the treatment programs have just fin-
ished. The final assessment occurs ten months after the
baseline assessment, in order to evaluate longer-term
effects of the treatments. The contents of the assessments
are outlined in figure 3 and explained in the following sec-
tions. The standard assessments are conducted at all three
assessment points.
*Severity of abuse
Assessment of number of days with cannabis use in the
past 30 days will be measured at all three assessment
points using the TLFB [29]. The TLFB has been reported to
have high validity in measuring cannabis consumption
when compared with urinalysis [30]. Briefly, the TLFB is a
self-reported measurement tool in which the respondent
plots all memorable dates within a preceding period on a
calendar, and then uses these dates to aid in remembering
consumption of a given substance on each day in the
period. If the patients consent, self-reported cannabis con-
sumption will be validated with blood samples.
Apart from using the TLFB, information will be obtained
about age of first use of cannabis, age of first regular use of
cannabis, and reasons for use of cannabis.
*Influence and severity of other substance use
The WHO's Schedules for Clinical Assessment in Neu-
ropsychiatry (SCAN) interview's chapters 11 and 12,
excluding the section on nicotine, will be used to estimate
influence and severity of other substance use, as well as
influence of cannabis abuse [41]. Chapter 11 measures
influence and severity of alcohol use, and chapter 12 of
other psychoactive substances, including prescription
medicine.
*Psychosis symptoms and clinical improvement
Psychosis symptoms are assessed by the use of The Posi-
tive and Negative Syndrome Scale (PANSS) for schizo-
phrenia [42]. Changes in PANSS scores have been shown
to correlate well with clinical improvements as measured
by the Clinical Global Impressions Ratings (CGI) scale
[43-45]. Furthermore, the overall impression of symp-
toms and functioning is evaluated using the Global
Assessment of Functioning (GAF) scale [46,47].
*Cognitive function
Various aspects of cognitive function will be measured
using a range of psychometric instruments. Prepsychotic
intelligence will be estimated using the Danish Adult
Reading Test (DART), a Danish adaptation of the
National Adult Reading Test [48]. Speed of information
processing will be assessed using the Brief Assessment of
Cognition in Schizophrenia (BACS) symbol coding and
Trail Making Part A [49-51]. Attention and vigilance are
assessed by Continuous Performance Test, Identical Pairs
version (CPT-IP) [52]. Working memory is assessed using
Trail Making Part B. Memory and verbal learning are
assessed with Hopkins Verbal Learning Test [53]. Execu-
Assessment tools used in the CapOpus trial Figure 3
Assessment tools used in the CapOpus trial.Trials 2008, 9:42 http://www.trialsjournal.com/content/9/1/42
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tive functioning is assessed with Neuropsychological
Assessment Battery (NAB) Mazes [54].
*Social functioning and quality of life
Social functioning within the major life areas of commu-
nity, social, and civil life will be estimated using the 12-
item interviewer administered version of the World
Health Organization's Disability Assessment Schedules
(WHODAS-II) [55]. Two measures of quality of life
(QOL) will be used in a combined attempt to compare
QOL improvements in the two treatment arms, namely
the five-item EQ-5D [56] and the seventeen-item Man-
chester Short Assessment of Quality of Life (MANSA) [57].
*Sociodemographic variables
A number of sociodemographic variables will be assessed,
including age, sex, living conditions, marital status, educa-
tion, employment status, number of children, ethnicity,
and history of homelessness.
*Other assessment tools
All of the assessment tools mentioned above will form the
standard assessments that will be used at all three assess-
ment points and on all patients. In addition, a few other
assessment tools will be used. At six months follow up,
user satisfaction with the received treatment will be evalu-
ated using the eight-item Client Satisfaction Question-
naire (CSQ) [58]. Adherence to the CapOpus intervention
will be measured by number of contacts between CapO-
pus consultants on one side and the patient, the patient's
family, and the patient's case manager on the other side.
Finally, cost of treatment and cost-benefit estimation will
be performed by comparing number of outpatient treat-
ments and number of bed days in the two treatment arms.
This will be done register-based in The Danish Psychiatric
Central Register [59,60] and The Danish National Hospi-
tal Register [61], as all persons in Denmark are easily iden-
tifiable in registers using a unique personal identification
number given to all people either at birth or upon migra-
tion into Denmark [62].
Randomization and blinding
Randomization into one of the two treatment arms is per-
formed after the baseline assessment. Firstly, randomiza-
tion is stratified by severity of cannabis abuse as measured
by TLFB, by creating two sub-strata; one of patients having
used cannabis less than 15 days in the preceding 30 day
period, and one of patients having used cannabis 15 days
or more. This is done to avoid the risk of heavy-users of
cannabis being overrepresented in either of the treatment
groups. Similarly, randomization will be stratified based
on the referrer – OPUS, CMHC, or ACT, as it is unlikely
that patients from these three referrers are comparable
with regard to psychotic symptoms and level of function-
ing.
The Copenhagen Trial Unit (CTU) will perform the cen-
tralized randomization, and only the CTU will know the
block size used to randomize. A research assistant pro-
vides information on the patients to the CTU after con-
ducting the baseline assessment. The CTU then performs
the randomization procedure based on computer-gener-
ated allocation sequences, and communicates the allo-
cated treatment to the CapOpus consultants responsible
for the CapOpus experimental intervention. If a patient is
allocated to CapOpus intervention, the consultants con-
tact the patient. Regardless of allocation, the consultants
also contact the patient's case manager, so that the treat-
ment as usual intervention can be commenced. This pro-
cedure ensures that the research assistant, who will be
doing the subsequent patient assessments, is blinded to
the allocated intervention. Blinding is maintained until
the end of the trial. Patients are instructed not to reveal
details that may cause the research assistant to deduce
which treatment they are receiving. At each of the follow-
up assessments, the research assistant will register a guess
as to which treatment the patient is receiving. When the
trial is finished, inter-rater reliability between the actual
treatment and the research assistant's guess will be esti-
mated using Cohen's kappa coefficient [63] to assess the
degree to which blinding has been successful.
Sample size and power calculation
A 2008 Cochrane review of psychosocial interventions for
people with both severe mental illness and substance mis-
use [28] identified five papers with results from studies
using a combination of motivational interviewing and
cognitive behavioral therapy.[22,64-67] However, only
one of these contains information about reduction of days
with cannabis abuse, but presents only the median, not
the mean, and the range, not the standard deviation.[22]
However, 6 months after start of treatment, this particular
paper reported that those receiving integrated care had, as
median, 20.62 percent of days abstinent from all sub-
stances, compared to 1.10 in the routine care group, i.e. a
difference of 19.5. Extrapolating this to our study, with a
TLFB-period of 30 days, corresponds to 5.85 days. Trun-
cating this to a more conservative 5 days, and assuming a
standard deviation also of 5 days, it becomes possible to
calculate sample size for an independent samples t-test;
with an α-level of 0.05 and a power of 0.90, the required
number of patients in each intervention can be calculated
to be 22. Due to attrition, more patients will be required.
Results from the OPUS trial, which may be comparable to
our study in terms of participant profiles, showed that
high attrition may be expected among substance-using
people with schizophrenia [38]. We obtained data about
one-year dropout from the OPUS trial among people with
substance misuse, and found that among those receiving
the control treatment, the dropout-rate was 37%. Gener-
alizing this to our study, regardless of intervention alloca-Trials 2008, 9:42 http://www.trialsjournal.com/content/9/1/42
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tion, at least 35 patients will be required in each of the two
intervention groups. However, we aim to include between
60 and 70 patients in each group, as this would enable us
to stratify the analyses. With 60 or 70 patients, it should
also be possible to measure even smaller differences in
secondary outcomes.
Statistics
The main null-hypothesis to be tested is that there is no
difference between the two treatment arms with regard to
decrease in cannabis use. All randomized patients will be
analyzed, including those who stop receiving treatment,
according to the intent-to-treat principle [68]. Continu-
ous outcome measures, including the primary outcome of
reduction of days with cannabis abuse, will be analyzed
using multivariate analysis of variance (ANOVA) mixed
models with repeated measurements. This will include
interaction analyses of time and type of treatment, in
order to evaluate the effect over time. Binary outcome
measures will be analyzed using multivariate logistic
regression models. The subgroup of patients who com-
plete the entire experimental treatment will be compared
with all those randomized into the trial in order to deter-
mine risk factors for attrition. Sensitivity analyses will be
carried out to evaluate the effect of treatment in patients
that are inaccessible for follow-up. This will be conducted
by multiple imputation methodology both using last
observation carried forward, and assuming an increase in
cannabis use among those lost to follow-up.
Ethical considerations
The regional ethics committee for the greater Copenhagen
area has approved the protocol under the file number H-
D-2007-0028, as has The Danish Data Protection Agency
under the file number 2007-41-0616. The trial is regis-
tered at ClinicalTrials.gov as NCT00484302. Both positive
and negative findings from the trial will be published, in
accordance with the CONSORT guidelines [69,70].
Information about the trial is presented to potential par-
ticipants both verbally and in written form. It is stressed
that participation is voluntary, without expected negative
side effects, and that the patient can withdraw his or her
consent at any time without consequence for treatment
possibilities. Patients will receive a copy of their rights.
Discussion
The centralized randomization procedure offers strengths
to the CapOpus trial by reducing the risk of selection and
allocation bias [71,72]. The outcome assessments are
blinded with the intent of being unbiased [71,72]. The
planned intense follow up of patients coupled with inten-
tion-to-treat analyses should guard against attrition bias
[71,72]. Also, the broad array of outcome estimates allows
us to measure effects of treatment in many areas of life.
Apart from gathering evidence about best practice in treat-
ment of cannabis abuse among young people with psy-
chosis, the study will allow us to validate the TLFB
measurement tool for cannabis against blood samples,
something that to our knowledge has not been done pre-
viously.
Hopefully, the CapOpus intervention will carry positive
effects. If this is so, this could substantially improve treat-
ment of these patients. On the other hand negative conse-
quences cannot be ruled out. The extra interventions in
the experimental arm may potentially cause more patients
to drop out from usual treatment. Should this occur, the
addiction consultants in CapOpus will actively support
the patients in resuming contact with the case managers.
Our trial may have several limitations. First, it is a rather
small trial aiming at demonstrating a substantial interven-
tion effect. In a sense, our trial may be viewed as a pilot for
potentially larger trials at a later stage. Second, the large
number of outcomes makes interpretation of significant
findings difficult. Accordingly, our interpretation of sig-
nificant findings at or close to the conventional level of p
= 0.05 will be conservative. One further limitation of the
trial is that there may be a crossover relating to the
patients' case-managers. Due to the randomization proce-
dure, the same case manager may have patients in both
the experimental intervention and the control treatment
arms. This spawns the risk that elements from the experi-
mental intervention are incorporated into the treatment
of patients in the control arm, potentially leading towards
type II errors. It will be attempted to bypass this limitation
by investigating outcome differences between control-
group patients whose case managers also have patients in
the CapOpus experimental intervention arm, and those
whose case managers do not.
The fact that the current treatment in Denmark is not uni-
form is reflected in the control treatment, as no attempts
will be made to artificially introduce a level of homogene-
ity in this intervention arm. This may, however, lead to a
degree of selection bias if only a small proportion of eligi-
ble case managers actually refer patients to the trial.
Results will be interpreted accordingly.
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